Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Peter Holicek"'
Autor:
Peter Holicek, Iva Truxova, Jana Rakova, Cyril Salek, Michal Hensler, Marek Kovar, Milan Reinis, Romana Mikyskova, Josef Pasulka, Sarka Vosahlikova, Hana Remesova, Iva Valentova, Daniel Lysak, Monika Holubova, Petr Kaspar, Jan Prochazka, Lenka Kasikova, Radek Spisek, Lorenzo Galluzzi, Jitka Fucikova
Publikováno v:
Cell Death and Disease, Vol 14, Iss 3, Pp 1-12 (2023)
Abstract While type I interferon (IFN) is best known for its key role against viral infection, accumulating preclinical and clinical data indicate that robust type I IFN production in the tumor microenvironment promotes cancer immunosurveillance and
Externí odkaz:
https://doaj.org/article/f8edc52886a84c80a88c6cee32d03c15
Autor:
Michal Hensler, Jana Rakova, Lenka Kasikova, Tereza Lanickova, Josef Pasulka, Peter Holicek, Marek Hraska, Tereza Hrnciarova, Pavla Kadlecova, Andreu Schoenenberger, Klara Sochorova, Daniela Rozkova, Ludek Sojka, Jana Drozenova, Jan Laco, Rudolf Horvath, Michal Podrazil, Guo Hongyan, Tomas Brtnicky, Michal J. Halaska, Lukas Rob, Ales Ryska, An Coosemans, Ignace Vergote, Abhishek D. Garg, David Cibula, Jirina Bartunkova, Radek Spisek, Jitka Fucikova
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
Dendritic cells (DCs) have received considerable attention as potential targets for the development of novel cancer immunotherapies. However, the clinical efficacy of DC-based vaccines remains suboptimal, largely reflecting local and systemic immunos
Externí odkaz:
https://doaj.org/article/8aa6cc35d16f49fbb0529e5fcefe2e0f
Autor:
Jana Rakova, Iva Truxova, Peter Holicek, Cyril Salek, Michal Hensler, Lenka Kasikova, Josef Pasulka, Monika Holubova, Marek Kovar, Daniel Lysak, Justin P. Kline, Zdenek Racil, Lorenzo Galluzzi, Radek Spisek, Jitka Fucikova
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Accumulating evidence indicates that immune checkpoint inhibitors (ICIs) can restore CD8+ cytotoxic T lymphocyte (CTL) functions in preclinical models of acute myeloid leukemia (AML). However, ICIs targeting programmed cell death 1 (PDCD1, best known
Externí odkaz:
https://doaj.org/article/7aa2896ab527498bac5610f866169e29
Autor:
Iva Truxova, Lenka Kasikova, Cyril Salek, Michal Hensler, Daniel Lysak, Peter Holicek, Pavla Bilkova, Monika Holubova, Xiufen Chen, Romana Mikyskova, Milan Reinis, Marek Kovar, Barbora Tomalova, Justin P. Kline, Lorenzo Galluzzi, Radek Spisek, Jitka Fucikova
Publikováno v:
Haematologica, Vol 105, Iss 7 (2020)
In some settings, cancer cells responding to treatment undergo an immunogenic form of cell death that is associated with the abundant emission of danger signals in the form of damage-associated molecular patterns. Accumulating preclinical and clinica
Externí odkaz:
https://doaj.org/article/d4f009b05a7b49c99d90bd4cbfda5580
Autor:
Jitka Fucikova, Lenka Palova-Jelinkova, Vanessa Klapp, Peter Holicek, Tereza Lanickova, Lenka Kasikova, Jana Drozenova, David Cibula, Beatriz Álvarez-Abril, Elena García-Martínez, Radek Spisek, Lorenzo Galluzzi
Publikováno v:
Trends in Cancer. 8:426-444
At odds with other solid tumors, epithelial ovarian cancer (EOC) is poorly sensitive to immune checkpoint inhibitors (ICIs), largely reflecting active immunosuppression despite CD8
Autor:
Iva Truxova, Radek Spisek, Monika Holubova, Barbora Tomalova, Jitka Fucikova, Pavla Bilkova, Peter Holicek, Romana Mikyšková, Marek Kovar, Xiufen Chen, Lenka Kasikova, Justin Kline, Daniel Lysák, Milan Reinis, Lorenzo Galluzzi, Michal Hensler, Cyril Salek
Publikováno v:
Haematologica
In some settings, cancer cells responding to treatment undergo an immunogenic form of cell death that is associated with the abundant emission of danger signals in the form of damage-associated molecular patterns. Accumulating preclinical and clinica
Autor:
Marek Kovar, Lorenzo Galluzzi, Jana Rakova, Justin Kline, Jitka Fucikova, Peter Holicek, Josef Pasulka, Monika Holubova, Iva Truxova, Zdenek Racil, Radek Spisek, Daniel Lysák, Cyril Salek, Michal Hensler, Lenka Kasikova
Publikováno v:
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
Accumulating evidence indicates that immune checkpoint inhibitors (ICIs) can restore CD8+ cytotoxic T lymphocyte (CTL) functions in preclinical models of acute myeloid leukemia (AML). However, ICIs targeting programmed cell death 1 (PDCD1, best known
Autor:
Marek Kovar, Justin Kline, Xiufen Chen, Pavla Bilkova, Jitka Fucikova, Cyril Salek, Lenka Kasikova, Monika Holubova, Iva Truxova, Daniel Lysák, Radek Spisek, Peter Holicek, Milan Reinis, Lorenzo Galluzzi, Barbora Tomalova, Romana Mikyšková, Michal Hensler
Publikováno v:
E-Poster Presentations.
In some settings, cancer cells responding to treatment undergo an immunogenic form of cell death that is associated with the abundant emission of danger signals in the form of damage-associated molecular patterns. Accumulating preclinical and clinica
Autor:
Iva Truxova, Radek Spisek, Monika Holubova, Jana Rakova, Peter Holicek, Daniel Lysák, Cyril Salek, Isabelle Cremer, Lenka Kasikova, Sarka Vosahlikova, Jitka Fucikova
Natural killer (NK) cells constitute the predominant innate lymphocyte subset that mediates the anti-viral and anti-tumor immune responses. NK cells use an array of innate receptors to sense their environment and to respond to infections, cellular st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d46df00785367bc211d6c766b449e68f
https://doi.org/10.1016/bs.mie.2019.05.034
https://doi.org/10.1016/bs.mie.2019.05.034
Autor:
Pavla Bilkova, Lorenzo Galluzzi, Michal Hensler, Peter Holicek, Milan Reiniš, Xiufen Chen, Monika Holubova, Marek Kovar, Barbora Tomalova, Justin Kline, Iva Truxova, Radek Spisek, Daniel Lysák, Jitka Fucikova, Lenka Kasikova, Cyril Salek, Romana Mikyšková
Publikováno v:
Cancer Immunology Research. 8:B96-B96
In some settings, cancer cells responding to treatment undergo an immunogenic form of cell death that is associated with the abundant emission of danger signals in the form of damage-associated molecular patterns (DAMPs). Accumulating preclinical and